Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

301. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. Full Text available with Trip Pro

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug that dissociates bone remodeling by increasing bone formation and decreasing bone resorption, has been shown to reduce the risk of vertebral fractures and to increase bone mineral density.To evaluate (...) the efficacy of strontium ranelate in preventing vertebral fractures in a phase 3 trial, we randomly assigned 1649 postmenopausal women with osteoporosis (low bone mineral density) and at least one vertebral fracture to receive 2 g of oral strontium ranelate per day or placebo for three years. We gave calcium and vitamin D supplements to both groups before and during the study. Vertebral radiographs were obtained annually, and measurements of bone mineral density were performed every six months.New

2004 NEJM Controlled trial quality: uncertain

302. Ten years' experience with alendronate for osteoporosis in postmenopausal women. Full Text available with Trip Pro

Ten years' experience with alendronate for osteoporosis in postmenopausal women. Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years.The initial three-year phase of the study compared three daily doses of alendronate with placebo. Women in the original placebo group received alendronate in years 4 and 5 and then were

2004 NEJM Controlled trial quality: uncertain

303. Does this woman have osteoporosis?

Does this woman have osteoporosis? Does this woman have osteoporosis? Does this woman have osteoporosis? Green A D, Colon-Emeric C S, Bastian L, Drake M T, Lyles K W CRD summary This review evaluated the diagnostic accuracy of physical examination for osteopenia, osteoporosis and spinal fracture. The authors concluded that several parameters could help to identify those with osteoporosis or spinal fractures, and women who would benefit from earlier screening. The conclusions of this review (...) are likely to be reliable. Authors' objectives To evaluate the diagnostic accuracy and precision of physical examination for osteopenia, osteoporosis and spinal fracture. Searching MEDLINE was searched from 1966 to August 2004; the search terms were reported. The reference lists of retrieved articles, reviews and clinical skills textbooks were also checked. Experts in the field were contacted. Study selection Study designs of evaluations included in the review There were no specific inclusion criteria

2004 DARE.

304. Development and validation of a new clinical risk index for prediction of osteoporosis in Thai women

Development and validation of a new clinical risk index for prediction of osteoporosis in Thai women Development and validation of a new clinical risk index for prediction of osteoporosis in Thai women Development and validation of a new clinical risk index for prediction of osteoporosis in Thai women Pongchaiyakul C, Nguyen N D, Pongchaiyakul C, Nguyen T V Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A new Thai-specific osteoporosis score, the Khon Kaen Osteoporosis Study (KKOS) score, was examined. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population The study population comprised the general population of women who might be at risk of osteoporosis. Women were

2004 NHS Economic Evaluation Database.

305. Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents

Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents Singh S, Sun H Y, Anis A H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the Impact hip protector (High Tech Bodywear Ltd.), a hard-shell protector with a soft inner lining, for the prevention of osteoporosis-related hip fractures in a high-risk Canadian nursing home population. Type of intervention Primary prevention. Economic study type Cost

2004 NHS Economic Evaluation Database.

306. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study

Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Borgstrom F, Johnell O, Kanis J A, Oden A, Sykes D, Jonsson B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of raloxifene (60 mg/day), a selective oestrogen receptor modulator, for the treatment of osteoporosis in postmenopausal women. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost

2004 NHS Economic Evaluation Database.

307. Compliance with drug therapies for the treatment and prevention of osteoporosis

Compliance with drug therapies for the treatment and prevention of osteoporosis Compliance with drug therapies for the treatment and prevention of osteoporosis Compliance with drug therapies for the treatment and prevention of osteoporosis McCombs J S, Thiebaud P, McLaughlin-Miley C, Shi J H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study looked at health technologies for the prevention and treatment of osteoporosis. In particular, oestrogens only, oestrogen plus progestin, raloxifene or bisphosphonate. Type of intervention Treatment Economic study type Cost-effectiveness analysis. Study population The study population comprised adult patients with a diagnosis of osteoporosis meeting various qualification

2004 NHS Economic Evaluation Database.

308. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

309. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women Full Text available with Trip Pro

Prevention of osteoporosis and osteoporotic fractures in postmenopausal women Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Synopsis W Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care Angela M (...) . Cheung , Denice S. Feig , Moira Kapral , Natalia Diaz-Granados , Sylvie Dodin and ; and The Canadian Task Force on Preventive Health Care Denice S. Feig Moira Kapral Natalia Diaz-Granados Sylvie Dodin Recommendations (see also ) Fig. 1: Recommendations of the Canadian Task Force on Preventive Health Care for the prevention of osteoporotic fractures in postmenopausal women. This algorithm excludes women with secondary osteoporosis (e.g., those who have hyperparathyroidism or are taking steroids

2004 CPG Infobase

310. Risedronate for the prevention and treatment of postmenopausal osteoporosis. (Abstract)

Risedronate for the prevention and treatment of postmenopausal osteoporosis. Postmenopausal osteoporosis results in an increased susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Risedronate, a third generation bisphosphonate, has been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density in postmenopausal women with osteoporosis. First and second generation bisphosphonates are known to have (...) gastrointestinal side-effects and risedronate may be better tolerated.To systematically review the efficacy of risedronate on bone density, and fracture reduction in postmenopausal women.The Cochrane Controlled Trials Registry Medline, and Current Contents were searched from 1990 - 2001. The electronic search was supplemented by handsearching four osteoporosis journals and their conference proceedings, as well as contacting content experts and industry sources for unpublished data.We included eight trials

2003 Cochrane

311. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. Full Text available with Trip Pro

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption. We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone.A total of 238 (...) postmenopausal women (who were not using bisphosphonates) with low bone mineral density at the hip or spine (a T score of less than -2.5, or a T score of less than -2.0 with an additional risk factor for osteoporosis) were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months. Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative

2003 NEJM Controlled trial quality: uncertain

312. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. (Abstract)

The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone mineral density.We randomly assigned 83 men who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (40 microg subcutaneously daily; 27 men), or both (28 men

2003 NEJM Controlled trial quality: uncertain

313. Osteoporosis - prevention, diagnosis and treatment

Osteoporosis - prevention, diagnosis and treatment Osteoporosis - prevention, diagnosis and treatment Osteoporosis - prevention, diagnosis and treatment Hagenfeldt K, Johansson C, Johnell O, Ljunggren O, Moller M, Morland B, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hagenfeldt K, Johansson C, Johnell O, Ljunggren O, Moller M (...) , Morland B, et al. Osteoporosis - prevention, diagnosis and treatment. Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2003 Authors' objectives The aim of this project was to systematically and critically assess the scientific evidence on the effectiveness of various interventions for the prevention, diagnosis and treatment of osteoporosis. Authors' conclusions Osteoporosis is a common condition in Sweden. One in three women aged 70 through 79 years is found to have

2003 Health Technology Assessment (HTA) Database.

314. Treating osteoporosis with teriparatide: many unknowns?

Treating osteoporosis with teriparatide: many unknowns? Treating osteoporosis with teriparatide: many unknowns? Treating osteoporosis with teriparatide: many unknowns? Shukla V Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shukla V. Treating osteoporosis with teriparatide: many unknowns? Ottawa: Canadian Coordinating Office for Health (...) Technology Assessment (CCOHTA) 2003 Authors' objectives To summarize the available information on the use of teriparatide (rDNA origin) injections (Forteo(TM), manufactured by Eli Lilly and Company) to treat patients with osteoporosis who are at high risk for fracture. Authors' conclusions Because of the safety concerns and the lack of efficacy and effectiveness data, it is difficult to define teriparatide's role in the treatment of osteoporosis. This is compounded by the possible long-term antagonizing

2003 Health Technology Assessment (HTA) Database.

315. Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis

Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis Miller P CRD summary This review assessed 1-year vertebral fracture risk reduction in treatments for osteoporosis. The author concluded that risedronate reduced the risk of fractures and that post hoc analyses have shown alendronate (...) and raloxifene to be effective. These conclusions were, in part, based upon an inappropriate interpretation of the results and, therefore, are likely to be unreliable. Authors' objectives To assess 1-year vertebral fracture risk reduction in adults with postmenopausal or glucocorticoid-induced osteoporosis. Searching MEDLINE was searched from 1990 onwards, and the bibliographies of selected citations and recent meeting abstracts were checked for studies reported in English. Study selection Study designs

2003 DARE.

316. Comparing therapies for postmenopausal osteoporosis prevention and treatment

Comparing therapies for postmenopausal osteoporosis prevention and treatment Comparing therapies for postmenopausal osteoporosis prevention and treatment Comparing therapies for postmenopausal osteoporosis prevention and treatment Eichner S F, Lloyd K B, Timpe E M CRD summary This review compared therapies for the prevention and treatment of osteoporosis in postmenopausal women. The authors concluded that several therapeutic options were found to improve bone mineral density and reduce the risk (...) of bone fractures. The review had several methodological weaknesses and was poorly reported. More focused and better-reported reviews are required to verify the conclusions. Authors' objectives To evaluate the efficacy of calcium and vitamin D supplementation, hormone replacement therapy (HRT), bisphosphonates, selective oestrogen receptor modulators (SERMs) and calcitonin in the prevention and treatment of osteoporosis in postmenopausal women. Searching MEDLINE (from 1966 to July 2002), EMBASE (from

2003 DARE.

317. Osteoporosis - prevention, diagnosis and treatment</a>

Osteoporosis - prevention, diagnosis and treatment Osteoporosis – prevention, diagnosis and treatment We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Osteoporosis – prevention, diagnosis and treatment Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Aim (...) Osteoporosis results from a reduction in the quantity of bone tissue and the deterioration of bone microstructure, leading to a general loss in bone strength and greater fracture risk. While part of the natural aging process, osteoporosis doesnt affect everyone to the same degree. The condition is common in Sweden, the annual socioeconomic costs for osteoporosis and related fractures coming to 3.5 billion kronor. The scientific literature on prevention, diagnosis and treatment of osteoporosis

2003 Swedish Council on Technology Assessement

318. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. (Abstract)

Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. Epidemiologic studies suggest that genetic factors confer a predisposition to the formation of renal calcium stones or bone demineralization. Low serum phosphate concentrations due to a decrease in renal phosphate reabsorption have been reported in some patients with these conditions, suggesting that genetic factors leading to a decrease in renal phosphate

2002 NEJM

319. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. (Abstract)

Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Although osteoporotic fractures present an enormous health burden, it is not clear whether screening to identify high-risk persons is appropriate.To examine evidence on the benefits and harms of screening postmenopausal women for osteoporosis.MEDLINE (1966 to May 2001), HealthSTAR (1975 to May 2001), and Cochrane databases; reference lists; and experts.English-language abstracts (...) that included original data about postmenopausal women and osteoporosis and addressed the effectiveness of risk factor assessment, bone density tests, or treatment were included.Selected information about patient population, interventions, clinical end points, and study design were extracted, and a set of criteria was applied to evaluate study quality.No trials of the effectiveness of screening have been published. Instruments developed to assess clinical risk factors for low bone density or fractures have

2002 Annals of Internal Medicine

320. Treatment of postmenopausal osteoporosis. (Abstract)

Treatment of postmenopausal osteoporosis. The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and nasal calcitonin, greatly reduce the risk of vertebral fractures. Furthermore, a large reduction of non (...) -vertebral fractures has been shown for alendronate, risedronate, and the 1-34 fragment of parathyroid hormone. Calcium and vitamin D supplementation is not sufficient to treat individuals with osteoporosis but is useful, especially in elderly women in care homes. Hormone replacement therapy remains a valuable option for the prevention of osteoporosis in early postmenopausal women. Choice of treatment depends on age, the presence or absence of prevalent fractures, especially at the spine, and the degree

2002 Lancet